Last reviewed · How we verify
Erlotinib HCl 150 mg
Erlotinib HCl 150 mg is a Small molecule drug developed by Quadras Scientific Solutions. It is currently FDA-approved.
At a glance
| Generic name | Erlotinib HCl 150 mg |
|---|---|
| Sponsor | Quadras Scientific Solutions |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations (PHASE3)
- Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (PHASE1)
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (PHASE3)
- A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (PHASE2)
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (PHASE3)
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erlotinib HCl 150 mg CI brief — competitive landscape report
- Erlotinib HCl 150 mg updates RSS · CI watch RSS
- Quadras Scientific Solutions portfolio CI
Frequently asked questions about Erlotinib HCl 150 mg
What is Erlotinib HCl 150 mg?
Erlotinib HCl 150 mg is a Small molecule drug developed by Quadras Scientific Solutions.
Who makes Erlotinib HCl 150 mg?
Erlotinib HCl 150 mg is developed and marketed by Quadras Scientific Solutions (see full Quadras Scientific Solutions pipeline at /company/quadras-scientific-solutions).
What development phase is Erlotinib HCl 150 mg in?
Erlotinib HCl 150 mg is FDA-approved (marketed).
Related
- Manufacturer: Quadras Scientific Solutions — full pipeline
- Compare: Erlotinib HCl 150 mg vs similar drugs
- Pricing: Erlotinib HCl 150 mg cost, discount & access